Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy

M. H. Heinemann
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

The safety and efficacy of intravitreously administered ganciclovir sodium as sole treatment for cytomegalovirus retinitis complicating the acquired immunodeficiency syndrome was studied prospectively in seven patients. All but one of the patients had bilateral cytomegalovirus retinitis and none were able to tolerate therapy with systemically administered ganciclovir because of myelosuppression in six patients and hepatotoxicity in one patient. Intravitreal ganciclovir therapy was discontinued in two patients within the initial 2-week induction phase because of severe intractable thrombocytopenia in one patient and retinal detachment in the other. The retinal detachment could not be conclusively attributed to the injections and was probably a secondary complication of cytomegalovirus retinitis. The remaining five patients were treated weekly, with the course of therapy ranging from a minimum of 14 weeks (18 injections) to a maximum of 56 weeks (58 injections). The patients were followed up for an average of 23.5 weeks. All eyes responded to intravitreal therapy initially, while the six untreated control eyes with cytomegalovirus retinitis all demonstrated progression of disease. Two eyes relapsed while receiving intravitreal doses of 200 micrograms of ganciclovir sodium and were subsequently treated with 300 micrograms of ganciclovir sodium per injection. One eye responded to this regimen, while in the other one the disease progressed. In the long-term treatment group, one eye developed Staphylococcus epidermidis endophthalmitis, which was treated with vitrectomy and intravitreal and systemic antibiotics.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute Endophthalmitis Incidence: Intravitreal Triamcinolone
Westfall et al.
Arch Ophthalmol 2005;123:1075-1077.
ABSTRACT | FULL TEXT  

Intraocular Distribution of 70-kDa Dextran after Subconjunctival Injection in Mice
Kim et al.
IOVS 2002;43:1809-1816.
ABSTRACT | FULL TEXT  

Intravitreal Toxicology and Duration of Efficacy of a Novel Antiviral Lipid Prodrug of Ganciclovir in Liposome Formulation
Cheng et al.
IOVS 2000;41:1523-1532.
ABSTRACT | FULL TEXT  

New developments in sustained release drug delivery for the treatment of intraocular disease
VELEZ and WHITCUP
Br. J. Ophthalmol. 1999;83:1225-1229.
FULL TEXT  

HIV medicine: Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome
Eong et al.
Postgrad. Med. J. 1999;75:585-590.
ABSTRACT | FULL TEXT  

Treatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir Implant
Musch et al.
NEJM 1997;337:83-90.
ABSTRACT | FULL TEXT  

Ganciclovir
Crumpacker
NEJM 1996;335:721-729.
FULL TEXT  

Diseases of the Retina
D'Amico
NEJM 1994;331:95-106.
FULL TEXT